Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Levis

Showing results (1-10 of 107) with videos related to

Pageof 11
Sort By:
Current Opinion in Hematology|December 18, 2004
Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemiaMark Levis
Blood|May 27, 2017
Midostaurin approved for FLT3-mutated AMLMark Levis
Blood|November 21, 2024
The Aza/Ven reshuffleMark Levis
Hematology. American Society of Hematology. Education Program|December 10, 2013
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Mark Levis
Blood|March 30, 2019
Arsenic and old <i>FLT3</i>Mark Levis
Haematologica|May 28, 2021
Arsenic and all-<i>trans</i> retinoic acid for acute promyelocytic leukemia: yes, it really is as good as it seemsMark Levis
Blood Advances|January 4, 2018
The current therapeutic landscape of FLT3 inhibitorsMark Levis
The Journal of Experimental Medicine|June 23, 2017
FLT3 dancing on the stem cellMark Levis
Haematologica|December 7, 2005
FLT3 and acute myeloid leukemia: what is the wild type receptor up to?Mark Levis
Blood|October 19, 2013
Targeting IDH: the next big thing in AMLMark Levis
Pageof 11

Showing results (1-10 of 107) with videos related to

Sort By:
Pageof 11
Current Opinion in Hematology|December 18, 2004
Recent advances in the development of small-molecule inhibitors for the treatment of acute myeloid leukemiaMark Levis
Blood|May 27, 2017
Midostaurin approved for FLT3-mutated AMLMark Levis
Blood|November 21, 2024
The Aza/Ven reshuffleMark Levis
Hematology. American Society of Hematology. Education Program|December 10, 2013
FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013?Mark Levis
Blood|March 30, 2019
Arsenic and old <i>FLT3</i>Mark Levis
Haematologica|May 28, 2021
Arsenic and all-<i>trans</i> retinoic acid for acute promyelocytic leukemia: yes, it really is as good as it seemsMark Levis
Blood Advances|January 4, 2018
The current therapeutic landscape of FLT3 inhibitorsMark Levis
The Journal of Experimental Medicine|June 23, 2017
FLT3 dancing on the stem cellMark Levis
Haematologica|December 7, 2005
FLT3 and acute myeloid leukemia: what is the wild type receptor up to?Mark Levis
Blood|October 19, 2013
Targeting IDH: the next big thing in AMLMark Levis
Pageof 11